Acorda Therapeutics Stock Working Capital
| ACORDelisted Stock | USD 16.20 0.40 2.41% |
Acorda Therapeutics fundamentals help investors to digest information that contributes to Acorda Therapeutics' financial success or failures. It also enables traders to predict the movement of Acorda Stock. The fundamental analysis module provides a way to measure Acorda Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acorda Therapeutics stock.
Acorda |
Acorda Therapeutics Company Working Capital Analysis
Acorda Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Acorda Therapeutics Working Capital | (152.98 M) |
Most of Acorda Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acorda Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionIn accordance with the company's disclosures, Acorda Therapeutics has a Working Capital of (152.98 Million). This is 135.94% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The working capital for all United States stocks is 110.35% higher than that of the company.
Acorda Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acorda Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acorda Therapeutics could also be used in its relative valuation, which is a method of valuing Acorda Therapeutics by comparing valuation metrics of similar companies.Acorda Therapeutics is currently under evaluation in working capital category among its peers.
Acorda Fundamentals
| Return On Equity | -0.24 | |||
| Return On Asset | -0.0577 | |||
| Profit Margin | (2.15) % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 161.45 M | |||
| Shares Outstanding | 1.24 M | |||
| Shares Owned By Insiders | 0.69 % | |||
| Shares Owned By Institutions | 13.22 % | |||
| Number Of Shares Shorted | 8.1 K | |||
| Price To Earning | 0.95 X | |||
| Price To Book | 0.05 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 117.63 M | |||
| Gross Profit | 82.43 M | |||
| EBITDA | 8.4 M | |||
| Net Income | (252.85 M) | |||
| Cash And Equivalents | 20.7 M | |||
| Cash Per Share | 0.85 X | |||
| Total Debt | 190.9 M | |||
| Debt To Equity | 2.56 % | |||
| Current Ratio | 1.71 X | |||
| Book Value Per Share | (127.17) X | |||
| Cash Flow From Operations | (13.98 M) | |||
| Short Ratio | 1.84 X | |||
| Earnings Per Share | (203.57) X | |||
| Price To Earnings To Growth | 0.51 X | |||
| Target Price | 10.0 | |||
| Number Of Employees | 102 | |||
| Beta | 1.46 | |||
| Market Capitalization | 821.03 K | |||
| Total Asset | 117.75 M | |||
| Retained Earnings | (1.19 B) | |||
| Working Capital | (152.98 M) | |||
| Current Asset | 451.32 M | |||
| Current Liabilities | 90.59 M | |||
| Net Asset | 117.75 M |
About Acorda Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acorda Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acorda Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acorda Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Acorda Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acorda Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acorda Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Acorda Stock
| 0.52 | BKRKF | PT Bank Rakyat | PairCorr |
| 0.52 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.51 | BKRKY | Bank Rakyat | PairCorr |
| 0.49 | PPERY | Bank Mandiri Persero | PairCorr |
| 0.45 | PTBRY | Bank Negara Indonesia | PairCorr |
The ability to find closely correlated positions to Acorda Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acorda Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acorda Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acorda Therapeutics to buy it.
The correlation of Acorda Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acorda Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acorda Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acorda Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in Acorda Stock
If you are still planning to invest in Acorda Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acorda Therapeutics' history and understand the potential risks before investing.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |